SCHEMBL6468703

SCHEMBL6468703

COC(=O)[C@@H]1CCCN1C(=O)CNC(=O)OC(C)(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLK5 Q9Y337 1/20 0.53
ALDH1A1 P00352 3/20 0.51
MEN1 O00255 1/20 0.51
TSHR P16473 1/20 0.51
KMT2A Q03164 1/20 0.51
FKBP1A P62942 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 1/20 0.44
RAB9A P51151 1/20 0.44
POLB P06746 1/20 0.44
FAP Q12884 3/20 0.43
PREP P48147 2/20 0.43
PEPD P12955 2/20 0.43
DPP4 P27487 3/20 0.42
DPP8 Q6V1X1 2/20 0.42
DPP7 Q9UHL4 2/20 0.42
ACE P12821 1/20 0.42
MMP1 P03956 1/20 0.42
MMP9 P14780 1/20 0.42
MMP13 P45452 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14235217 1.00 KLK5 (0.53) KLK5ALDH1A1MEN1TSHRKMT2A
SCHEMBL31733808 0.96 FKBP1A (0.53) KLK5ALDH1A1MEN1TSHRKMT2A
Hydrochloric Acid SCHEMBL10983297 0.88 KLK5 (0.44) KLK5ALDH1A1MEN1TSHRKMT2A
SCHEMBL1925210 0.88 ACE (0.53) KLK5ALDH1A1MEN1TSHRKMT2A
SCHEMBL1000948 0.88 ACE (0.53) KLK5ALDH1A1MEN1TSHRKMT2A
SCHEMBL14979025 0.88 MEN1 (0.49) KLK5ALDH1A1MEN1TSHRKMT2A
SCHEMBL8352289 0.88 MEN1 (0.49) KLK5ALDH1A1MEN1TSHRKMT2A
SCHEMBL8350809 0.88 POLB (0.49) KLK5ALDH1A1FKBP1ASMN1; SMN2LMNA
SCHEMBL8135647 0.87 KLK5 (0.46) KLK5ALDH1A1MEN1TSHRKMT2A
SCHEMBL8135649 0.87 KLK5 (0.46) KLK5ALDH1A1MEN1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120004984-A Cyclic lactam compound and liquid phase synthesis method thereof 上海瑗肽生化科技有限公司 2025-05-16 CN disclosed
CN-120004974-A Liquid phase synthesis method of cyclic lactam compound 上海瑗肽生化科技有限公司 2025-05-16 CN disclosed
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 US disclosed
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 US disclosed
WO-2023064991-A1 PROCESS FOR PREPARING BICYCLIC GLYCINE-PROLINE COMPOUNDS AND MONOCYCLIC GLYCINE-PROLINE INTERMEDIATES THEREOF NEUREN PHARMACEUTICALS LIMITED (NZ) 2023-04-27 WO disclosed
EP-4121055-A1 STAT DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-01-25 EP disclosed
WO-2021188696-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed
EP-2195321-B1 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES AS INHIBITORS OF PROTEIN KINASE C PFIZER (US) 2016-10-19 EP disclosed
US-8999981-B2 3-amido-pyrrolo[3,4-C]pyrazole-5(1H, 4H,6H) carbaldehyde derivatives PFIZER INC. (US) 2015-04-07 US disclosed
US-20120108588-A1 NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES PFIZER, INC. (US) 2012-05-03 US disclosed
US-8114871-B2 3-amido-pyrrolo[3,4-C]pyrazole-5(1H,4H,6H) carbaldehyde derivatives PFIZER INC. (US) 2012-02-14 US disclosed
US-20100249128-A1 NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H,4H,6H) CARBALDEHYDE DERIVATIVES PFIZER INC. 2010-09-30 US disclosed
WO-2008125945-A2 3-AMIDO-PYRROLO [3, 4-C] PYRAZOLE-5 (1H, 4H, 6H) CARBALDEHYDE DERIVATIVES AS INHIBITORS OF PROTEIN KINASE C PFIZER INC. (US) 2008-10-23 WO disclosed
US-5583146-A Heterocyclic thrombin inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 1996-12-10 US disclosed
EP-0601459-A2 Sulfonamido heterocyclic thrombin inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 1994-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249128-A1 NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H,4H,6H) CARBALDEHYDE DERIVATIVES INSR, IAPP, PYCR1 KLK5 1756/4885ALDH1A1 367/4885MEN1 2099/4885
US-20120108588-A1 NOVEL 3-AMIDO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES INSR, IAPP, PYCR1 KLK5 1756/4885ALDH1A1 367/4885MEN1 2099/4885
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 KLK5 892/4885ALDH1A1 2465/4885MEN1 3280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.